Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.23 +1.85%

+$0.19 today

Market cap
$1.82B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 1.69M

Average 7.51M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$261.63M

FY 2025 · Annual

Net Income

-$247.30M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Revenue00000
Cost of Revenue4.14M4.58M000
Gross Profit(4.14M)(4.58M)000
Gross Margin—————
Research & Development57.49M80.65M126.53M174.96M189.45M
Selling, General & Admin21.13M36.26M000
Operating Expenses78.62M116.91M177.08M234.77M261.63M
Depreciation & Amortization4.14M4.58M2.45M5.08M5.93M
EBITDA(76.48M)(114.41M)(171.72M)(227.77M)(253.92M)
EBITDA Margin—————
Operating Income(82.76M)(121.48M)(177.08M)(234.77M)(261.63M)
Operating Margin—————
Interest Income916K390K10.01M23.36M21.12M
Interest Expense3.06M2.22M4.16M6.66M7.89M
Other Income / Expenses(915K)278K3.08M19.39M14.8M
Income Before Tax(83.68M)(121.21M)(174M)(215.39M)(246.83M)
Pre-Tax Margin—————
Income Tax Expense(2.81M)(3.17M)288K408K468K
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Net Margin—————
EPS (Basic)(1.75)(2.26)(2.99)(3.24)(3.07)
EPS (Diluted)(1.75)(2.26)(2.99)(3.24)(3.07)
Weighted Avg Shares46.25M52.21M58.21M66.57M80.56M
Weighted Avg Shares (Diluted)46.25M52.21M58.21M66.57M80.56M

REPL Earnings Waterfall · TTM

NASDAQ:REPL · Revenue to Net Income

Key Ratios

EPS$-3.58
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.4
P/S Ratio0.0

Analysis

$0 of revenue converted into -$314.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.58, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 10, 2026
SC 13G/ASC 13G/A filingNov 9, 2026
10-Q/A10-Q/A filingNov 6, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

How much revenue does REPL generate?

Replimune Group, Inc. (REPL) reported $0.00 of revenue in fiscal 2025.

Is REPL profitable?

Replimune Group, Inc. (REPL) reported -$247.30M of net income.